CSIMarket
 
Cartesian Therapeutics Inc   (SELB)
Other Ticker:  
 
 
Price: $0.8812 $-0.08 -7.997%
Day's High: $0.9399 Week Perf: -16.87 %
Day's Low: $ 0.81 30 Day Perf: -18.41 %
Volume (M): 2,774 52 Wk High: $ 1.76
Volume (M$): $ 2,445 52 Wk Avg: $1.18
Open: $0.89 52 Wk Low: $0.81



 Market Capitalization (Millions $) 136
 Shares Outstanding (Millions) 155
 Employees 60
 Revenues (TTM) (Millions $) 35
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -34
 Capital Exp. (TTM) (Millions $) 1

Cartesian Therapeutics Inc
Selecta Biosciences Inc is a clinical-stage biotechnology company that specializes in developing and commercializing targeted immunotherapies and vaccines to treat rare and severe diseases. The company was founded in 2008 and is headquartered in Watertown, Massachusetts.

Selecta's innovative technology platform, Synthetic Vaccine Particle (SVP), enables the design and development of highly specific and potent immunotherapies and vaccines that can selectively target and eliminate harmful cells while leaving healthy cells intact. The SVP platform uses biodegradable polymer nanoparticles that deliver the desired immunogen to specific antigen-presenting cells in the body. This approach results in a robust and targeted immune response that offers superior efficacy, safety, and tolerability compared to other therapies.

Selecta Biosciences' product pipeline includes therapies for rare and severe diseases such as Immune Tolerance Therapy (ITT) for celiac disease, SEL-212 for chronic refractory gout, and SEL-313 for Pompe disease. The company is also developing a universal flu vaccine using its SVP platform.

In December 2021, Selecta Biosciences announced that it had entered into a definitive merger agreement with Fortress Biotech, a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products. The merger is expected to provide Selecta with the financial and operational resources needed to advance its product pipeline and achieve its long-term strategic goals.

Additionally, Selecta Biosciences has formed strategic partnerships with leading pharmaceutical companies such as Sanofi, which is collaborating with Selecta to develop immunotherapies for food allergies. The company has also received funding support from several government agencies, including the National Institutes of Health (NIH), the Department of Defense (DOD), and the Bill and Melinda Gates Foundation.

In summary, Selecta Biosciences is a cutting-edge biotechnology company that is revolutionizing the field of personalized medicine with its innovative SVP platform. The company's strong product pipeline, strategic partnerships, and funding support make it a promising player in the biotech industry.


   Company Address: 65 Grove Street Watertown 2472 MA
   Company Phone Number: 923-1400   Stock Exchange / Ticker: NASDAQ SELB
   SELB is expected to report next financial results on March 01, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Cartesian Therapeutics on Track to Revolutionize Autoimmune Disease Treatment with Innovative mRNA Cell Therapies.

Published Mon, Jan 8 2024 12:10 PM UTC

Cartesian Therapeutics, a leading clinical-stage biotechnology company, has recently released an update on its progress and strategic priorities for 2024. The company's focus lies in the development of innovative mRNA cell therapies for autoimmune diseases. With the potential to revolutionize the treatment landscape, Cartesian Therapeutics is committed to advancing its pipel...

Cartesian Therapeutics Inc

Cartesian Therapeutics Inc. Faces Alarming Revenue Plunge, Raising Concerns About Financial Stability



Cartesian Therapeutics Inc, a major pharmaceutical preparations company, recently announced their financial results for the period ending September 30, 2023. The company reported a disastrous quarter, with a significant decline in revenue and widening of the shortfall per share compared to the same quarter last year. Additionally, Cartesian Therapeutics Inc experienced a higher net deficit and a decline in accounts receivable. These figures indicate troubling trends that raise concerns about the company's financial health.
1. Revenue Declines by -68.368%:
During the period ending September 30, 2023, Cartesian Therapeutics Inc reported a staggering decline of -68.368% in revenue, which plummeted to $6.55 million. This significant dip is an alarming development for the company and requires a thorough investigation into the factors contributing to this decline.

Selecta Biosciences Inc

Selecta Biosciences Inc Faces Challenging Quarter with Sharply Declining Revenue and Increased Losses



Selecta Biosciences Inc, a major player in the Pharmaceutical Preparations sector, recently disclosed its financial results for the period closing June 30, 2023. Unfortunately, the company experienced a disastrous financial interval marked by significant declines in revenue and increased losses per share. This article aims to outline the key facts from the financial results and provide an interpretation of the implications for Selecta Biosciences Inc.
Financial Results Overview:
1. Revenue Decline: Selecta Biosciences Inc witnessed a staggering 86.635% decline in revenue from the comparable reporting period a year earlier. This decrease resulted in a revenue of $5.25 million, indicating dwindling sales.

Selecta Biosciences Inc

Selecta Biosciences Inc Plunges into Deficit During First Quarter of 2023

Investing in the stock market can be an exciting yet nerve-wracking experience, but it's always important to stay up-to-date with the latest financial earnings for the companies you're invested in. In the case of Selecta Biosciences Inc, the first quarter of 2023 proved to be a bit of a disappointment with a $-0.14 per share shortfall compared to $0.08 from the year before. Despite this, there are still optimistic signs for investors to pay attention to.
One of the key factors that may bring hope to Selecta Biosciences Inc investors is the fact that the EPS fell from $0.01 per share from the prior reporting period. Though it's not ideal, it's not the biggest drop in earnings seen in the stock market. Furthermore, this decline could be viewed as an opportunity for investors to buy in at a lower price point and potentially see returns as the company rebounds in the future.






 

Cartesian Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com